Abstract:Dear Editor It was with a great interest that we have read the article entitled ‘Obstructive sleep apnea and biomarkers of inflammation in ischemic stroke’ by Medeiros et al. (1) published recently in this journal. After reading the article, we benefited a lot from it. In recent years, our institute has been studying the relationship between hypertension, stroke, coronary heart disease, and sleep apnea. Medeiros et al. encouraged us greatly. We would like to share our opinions about the study. The following suggestions are necessary to be considered. Obstructive sleep apnea syndrome (OSAS) is a sleep disorder characterized by recurrent episodes of oxygen desaturation during sleep, representing an independent risk factor for cardiovascular disease, such as stroke, myocardial infarction, congestive heart failure, and resistant hypertension. Studies have suggested a strong bidirectional association between OSAS and metabolic syndrome (MS) (2). The prevalence of OSAS and MS is increasing worldwide, in part linked to epidemic of obesity. The study (3) demonstrated that obese patients with OSAS patients may have an increased rate of MS, but body mass index (BMI) did not adequately describe regional (central) adiposity. The related findings suggested that abdominal obesity, representing abundant mesenteric fat tissue susceptible to hypoxic stress, reduction of visceral fat accumulation may combat OSAS-related atherosclerotic cardiovascular diseases in abdominal obesity (4).The waist circumference and waist–hip ratio seem to be better indicators of all-cause mortality than BMI (5). Atherosclerosis was no longer considered a disorder of lipid accumulation, but a disease process characterized by the dynamic interaction between endothelial dysfunction, subendothelial dysfunction, and inflammation. Prospective epidemiological studies have unequivocally demonstrated increased vascular risk in individuals with elevated levels of cytokines such as interleukin-6 (IL-6). Increased IL-6 expression has been associated with a variety of diseases, including inflammatory conditions such as atherosclerosis and cardiovascular disease. Inflammatory markers, in particular IL-6 and C-reactive protein, were more strongly associated with risk of fatal vascular events than non-fatal vascular events (6). So, the study should pay more attention to the coronary heart disease. Rupture of unstable atherosclerotic plaques is the pathological substrate for acute ischemic events. Early after stroke and transient ischemic attack, plaques revealed an unstable phenotype. After stroke, changes in IL-6 and IL-8 preceded the decrease of macrophages. These temporal phenotypic plaque alterations should be taken into account for biomarker and therapeutic target validation studies using human atherosclerotic plaques (7). Statins has dramatically reduced morbidity and mortality in patients with established cardiovascular disease. The benefit in reducing cardiovascular risk with statins has been attributed both to cholesterol lowering and pleiotropic effects. Statin therapy reduced inflammatory markers in a largely low-density lipoprotein (LDL)-independent manner, and the ‘anti-inflammatory’ properties of these agents have been suggested as a potential mechanism beyond LDL reduction for the efficacy of these agents. At last, even, the consumption of some typical Mediterranean foods was associated with lower serum concentrations of inflammatory markers especially those related to endothelial function, in subjects with high cardiovascular risk living in a Mediterranean country (8).

Changes in plasma concentrations of novel vascular and inflammatory biomarkers in obstructive sleep apnea patients pre- and post-stroke

Clinical Significance of Obstructive Sleep Apnea in Patients with Acute Coronary Syndrome with or Without Prior Stroke: a Prospective Cohort Study

The Complicated Relationship Between Obstructive Sleep Apnea and Inflammation Biomarkers

Altered amyloid-β and tau proteins in neural-derived plasma exosomes in obstructive sleep apnea

Effects of obstructive sleep apnea on inflammatory markers in patients with acute coronary syndrome

The Relationship Between Obstructive Sleep Apnea Hypopnea Syndrome and Inflammatory Markers and Quality of Life in Subjects With Acute Coronary Syndrome.

Phenotypic Characterisation of Obstructive Sleep Apnoea in Acute Coronary Syndrome

Clinical Utility of Biochemical Markers of Obstructive Sleep Apnea

0486 Performing Polysomnography in the Acute Post-stroke Setting

Sleep Biomarkers, Health Comorbidities, and Neurocognition in Obstructive Sleep Apnea

Biomarkers and Dynamic Cerebral Autoregulation of Obstructive Sleep Apnea-Hypopnea Syndrome

Neuroimaging consequences of cerebral small vessel disease in patients with obstructive sleep apnea-hypopnea syndrome.

0564 The mechanism of deficits in cognition of OSA: plasma amyloid-beta and tau protein level by the intervention design

Association of Polysomnographic Sleep Parameters With Neuroimaging Biomarkers of Cerebrovascular Disease in Older Adults With Sleep Apnea

Elevated tau and interleukin-6 concentrations in adults with obstructive sleep apnea

Effects of severe obstructive sleep apnea on functional prognosis in the acute phase of ischemic stroke and quantitative electroencephalographic markers.

Abstract TP251: The Influence of Obstructive Sleep Apnea on Post-Stroke Complications: A Systematic Review and Meta-Analysis

Abstract TMP52: Obstructive Sleep Apnea In Acute Ischemic Stroke Patients In The United States: Temporal Trends And Outcomes

Alzheimer's disease biomarkers in patients with obstructive sleep apnea hypopnea syndrome and effects of surgery: A prospective cohort study

0221 Effect of Acutely Induced OSA During SWS on AD Plasma Biomarkers

Impact of sleep disturbance on longitudinal cognitive performance in patients with transient ischemic attack or mild stroke